ACA
CRDF icon

Acorn Capital Advisors’s Cardiff Oncology CRDF Stock Holding History

Acorn Capital Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,762,084
Closed -$2.85M – 21
2026
Q1 		$2.85M Sell
1,762,084
-200,000
-10% -$411K 0.81% 16
2025
Q4 		$5.51M Hold
1,962,084
– – 1.87% 12
2025
Q3 		$4.04M Buy
1,962,084
+553,317
+39% +$1.53M 2.05% 12
2025
Q2 		$4.44M Sell
1,408,767
-33,541
-2% -$102K 2.9% 12
2025
Q1 		$4.53M Hold
1,442,308
– – 3.02% 13
2024
Q4 		$6.26M Buy
+1,442,308
New +$4.51M 3.37% 12

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Acorn Capital Advisors's CRDF Position: Q2 2026 in Review

Acorn Capital Advisors sold out of Cardiff Oncology (CRDF) in Q2 2026, closing a stake of 1,762,084 shares — an estimated $2.85M sold.

Acorn Capital Advisors first reported a position in CRDF in Q4 2024 and held it in 6 quarters. The position peaked at $6.26M in Q4 2024. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • Acorn Capital Advisors reported no remaining Cardiff Oncology position as of Q2 2026 after selling out during the quarter.
  • Acorn Capital Advisors sold 1,762,084 Cardiff Oncology shares in Q2 2026, an estimated $2.85M.
  • Acorn Capital Advisors first reported a position in Cardiff Oncology in Q4 2024 and held it in 6 quarters.
  • Acorn Capital Advisors's Cardiff Oncology position peaked at $6.26M in Q4 2024.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Acorn Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.